Search the Newsreel

ABUS|Arbutus Biopharma Corp|Price:4.710|Chg%:+0.130

Fennec Pharmaceuticals (FENC): Southpoint group files 13G/A showing 0% ownership

Southpoint-related entities and individual John S. Clark have filed an amended Schedule 13G/A for Fennec Pharmaceuticals Inc. (FENC), indicating that they now beneficially own 0 Common Shares, representing 0% of the class. This filing signifies that their ownership is 5 percent or less, with …

Sutro Biopharma (STRO): Point72 group reports 1.4% stake in 13G/A

Point72 Asset Management, along with Point72 Capital Advisors, Inc. and Steven A. Cohen, has filed an amended SCHEDULE 13G/A, reporting a 1.4% beneficial ownership stake in Sutro Biopharma (STRO). This represents 237,827 shares of common stock as of June 30, 2026, with shared voting …

Galmed Pharmaceuticals (GLMD) to implement 1-for-8 reverse share split in August 2026

Galmed Pharmaceuticals (GLMD) has announced a 1-for-8 reverse share split, consolidating its ordinary shares, with post-split trading expected to begin on August 19, 2026, on the Nasdaq Capital Market. This action will reduce the number of outstanding shares from 8,332,518 to approximately 1,041,565 and …

Amneal Pharmaceuticals (AMRX) director sells 50,000 shares, gifts 10,000 to charity

Amneal Pharmaceuticals director John Kiely reported selling 50,000 shares of Class A Common Stock at a weighted average price of $17.64 per share on August 13, 2026. Additionally, he made a charitable donation of 10,000 shares of Class A Common Stock to a donor-advised …

Vertex Pharmaceuticals (VRTX) Could Be 8% Undervalued Following Raised 2026 Guidance

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Vertex Pharmaceuticals (VRTX) has drawn fresh attention after reporting second quarter 2026 results, raising full year revenue guidance to US$13.1b to US$13.2b, and completing …

Lantern Pharma Reports 46.2% Wider Q2 2026 Loss at -$0.57/Share

Corbus Pharmaceuticals (CRBP): Citadel entities and Kenneth Griffin disclose 1.1% stake

Citadel-affiliated entities, including Kenneth Griffin, have disclosed a beneficial ownership of 206,354 shares in Corbus Pharmaceuticals Holdings, Inc. This represents a 1.1% stake in the company, based on 18,527,795 shares outstanding as of May 8, 2026. The filing indicates shared voting and dispositive power …

PMV Pharmaceuticals Releases Q2 2026 Financial Results

PMV Pharmaceuticals reported a narrower loss for Q2 2026, with a loss of $0.34 per share compared to $0.41 in the prior year, marking a 17.1% improvement. The precision oncology company recorded a net loss of $18.1 million as it continues to invest in …

Why Eton Pharmaceuticals Is Top of the Class Today

Key Points Eton Pharmaceuticals beat on both top and bottom lines last night. Management is licensing a new drug, and raising guidance through the end of 2026.10 stocks we like better than Eton Pharmaceuticals › Eton Pharmaceuticals (NASDAQ: ETON) stock soared 41.9% through 2:15 …

WST Stock Surges 38.1% Since March-End: What's Fueling the Rally?

West Pharmaceutical Services (WST) stock has seen a significant rally, surging 38.1% since the end of March, driven by strong organic revenue growth and increased adjusted EPS. The company benefits from high demand for its proprietary products, particularly those used in biologics, biosimilars, and …

Quoin Pharmaceuticals Releases Q2 2026 Financial Results

Quoin Pharmaceuticals (QNRX) announced its Q2 2026 financial results, reporting a diluted EPS of -$1.90, which is a significant improvement from the -$6.28 loss in Q2 2025. The company posted a net loss of $5.4 million for the quarter. Wall Street analysts currently have …

Innate Pharma Secures €30M, Extends Cash Runway Into 2028

Innate Pharma has secured €30 million in equity financing, which, combined with a potential €75 million upfront payment from its partnership with Sobi, is expected to extend its cash runway into the first quarter of 2028. This funding will support the development of lacutamab, …

Price-Driven Insight from (CRBP) for Rule-Based Strategy

This article provides a price-driven insight for Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), outlining near-term and mid-term strong sentiment but a weak long-term outlook. It details specific trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis and support/resistance …

Bernstein Lifts Regeneron Price Target to $756, Stays on Sidelines

Bernstein has raised its price target for Regeneron Pharmaceuticals to $756 from $753, while maintaining a Market Perform rating, indicating a slightly more positive near-term outlook but not a fundamental shift in its investment thesis. This new target remains below the Wall Street consensus …

Citius Pharmaceuticals (CTXR) holders report 3.0M-share, 9.9% beneficial stake

CVI Investments, Inc. and Heights Capital Management, Inc. have reported a beneficial ownership of 3,008,529 common shares in Citius Pharmaceuticals (CTXR), which represents a 9.9% stake. This position primarily consists of shares issuable upon the exercise of warrants, subject to beneficial ownership limits of …

Zenas BioPharma (ZBIO) Is Down 9.2% After Wider Losses And Leadership Changes - What's Changed

Zenas BioPharma reported widening losses in Q2 2026, with revenue dropping significantly year-over-year and net loss reaching US$111,460,000. These financial results were accompanied by leadership changes, including the CFO transitioning to a Strategic Advisor role and a new board appointment. The company's investment narrative …

Lantern Pharma (LTRN) Advances AI-Driven Oncology Pipeline Amid Valuation Challenges

Anuh Pharma Shareholders Clear Board Reappointments and Governance Updates

This Analyst Believes Eton Pharma’s Raised Guidance Is ‘Conservative’ – ETON Stock Heads For Best Ever Day

Eton Pharmaceuticals (ETON) shares surged 40% to an all-time high after better-than-expected Q2 results, driven by the successful relaunch of Hemangeol. The company raised its full-year 2026 revenue guidance to over $145 million and adjusted EBITDA margin to at least 35%. Analysts from B. …

Aspire BioPharma, Inc. (NASDAQ: ASBP) Share Price, ASBP Stock News, ASBP Share Price & Updates

Traws Pharma (TRAW) investor Squadron reports 0% beneficial ownership in 13G/A

Squadron Master Fund LP, Squadron Capital Management, LLC, Matthew Sesterhenn, and William Blank have filed an amended Schedule 13G (Amendment No. 4) for Traws Pharma (TRAW), reporting 0% beneficial ownership. The group now holds no shares of Traws Pharma common stock and possesses no …

ANIP's Cortrophin Guidance Cut Raises the Bar for Second-Half Growth

ANI Pharmaceuticals, Inc. ANIP topped second-quarter earnings and revenue expectations, but the quarter also exposed a softer result for Cortrophin Gel, its key growth driver. That tension matters because Cortrophin now carries more weight in the company's growth mix. ANI kept its broader 2026 …

Innate Pharma increases equity bookbuild by a third to €30m

Innate Pharma has increased its equity bookbuild by one-third to €30 million, driven by a new $75 million partnership to develop a lymphoma treatment. The article indicates that this partnership was a significant "catalyst for investors." The full details are available to subscribers of …

Mereo BioPharma (MREO): EcoR1 reports 0.6% passive stake via ADS holdings

EcoR1 Capital, LLC, Oleg Nodelman, and EcoR1 Capital Fund Qualified, L.P. have reported a passive beneficial ownership of 0.6% each in Mereo BioPharma Group plc. This stake, held through American Depositary Shares (ADS), represents 5,000,000 Ordinary Shares for EcoR1 and Nodelman, and 4,732,750 Ordinary …

Lantern Pharma outlines Open Medicine AI spin-out amid $10B market outlook by 2030-2031

Earnings Call Insights: Lantern Pharma (LTRN) Q2 2026 MANAGEMENT VIEW * “In August, we established Open Medicine AI as a separate company with commercial licenses and agreements with Lantern in place to take the AI data models to the next level,” said (President, CEO …

Immix Biopharma (NASDAQ:IMMX) Stock Price Down 4.5% - Here's Why

Immix Biopharma (NASDAQ: IMMX) shares dropped 4.5% to $10.43 on Friday, with trading volume significantly below average. This decline followed the company missing its latest quarterly earnings estimate, reporting a loss of $0.18 per share against an expected $0.17 loss. Despite the recent dip, …

Pharma Mar, S.A. : Top Fondos de inversión | PHM | ES0169501022

Pharma Mar, S.A. : Consenso de Precios Objetivo y Recomendaciones de los Analistas | PHM | ES0169501022

ETON Stock Soars After Huge Earnings Beat And Guidance Hike

Eton Pharmaceuticals (ETON) stock surged by over 40% after reporting Q2 revenue of $37.6 million, nearly double year-over-year and significantly beating consensus estimates, with adjusted EPS of $0.43. Management raised its 2026 revenue guidance to over $145 million and adjusted EBITDA margin to at …

Curanex Pharmaceuticals Inc Q2 2026: Net income $(3.29M), EPS $(0.12) — 10-Q Summary

Curanex Pharmaceuticals Inc (CURX) reported a net loss of $(3.29M) for Q2 2026, with a diluted loss per share of $(0.12), and no revenue as the company remains pre-revenue. This compares to a net loss of $(0.06M) in Q2 2025. The company completed a …

CURX: Net loss rose to $6.4M as R&D spending increased; cash shortfall raises going concern doubts

Curanex Pharmaceuticals Inc (CURX) reported a net loss of $6.4 million for the first half of 2026, primarily due to increased spending on R&D and administrative costs as its lead drug candidate progresses. The company faces significant going concern doubts as its current cash …

Conferencia de resultados del T2 de 2026 de Acumen Pharmaceuticals (ABOS): lectura de datos de ALTITUDE-AD prevista para finales de 2026

Acumen Pharmaceuticals (NASDAQ: ABOS) held its Q2 2026 earnings conference call, focusing on the upcoming Phase II ALTITUDE-AD trial results for sabirnetug, expected by late 2026. The company reported $110.2 million in cash and marketable securities, providing liquidity until early 2027, with a net …

Are You Looking for a Top Momentum Pick? Why Urogen Pharma (URGN) is a Great Choice

Urogen Pharma (URGN) is highlighted as a strong momentum pick due to its "A" Momentum Style Score from Zacks and a Zacks Rank of #2 (Buy). The article details URGN's impressive short-term and long-term price performance, outperforming both its industry and the S&P 500. …

Eton Pharmaceuticals Stock Jumps 38% as Guidance Reset Tests Valuation

Cue Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Cue Biopharma reported its second-quarter 2026 financial results, highlighting a significant increase in revenue due to a collaboration milestone and higher expenses related to the CUE-221 development program. The company also announced the submission of an IND for CUE-221 in food allergy applications, a …